Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 14, 2005

 

 

TERCICA, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

000-50461   26-0042539
(Commission File Number)   (IRS Employer Identification No.)

 

2000 Sierra Point Parkway, Suite 400

Brisbane, CA 94005

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (650) 624-4900

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01. Other Events.

 

On August 14, 2005, Tercica, Inc. issued a press release announcing that Insmed Incorporated has filed a Citizen Petition to immediately deny approval of Tercica’s NDA for Increlex™. A copy of the press release concerning the foregoing is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(c) Exhibits

 

Number
  

Description

99.1   Press Release entitled “Tercica Announces Insmed Files Citizen Petition with the FDA to Deny Approval of Increlex NDA,” dated August 14, 2005.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TERCICA, INC.
Dated: August 15, 2005   By:  

/S/ STEPHEN N. ROSENFIELD

       

Stephen N. Rosenfield

Senior Vice President of Legal Affairs

EXHIBIT INDEX

 

Number
  

Description

99.1   Press Release entitled “Tercica Announces Insmed Files Citizen Petition with the FDA to Deny Approval of Increlex NDA,” dated August 14, 2005.